Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 1436

1.

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S.

N Engl J Med. 2016 Jun 23;374(25):2419-29. doi: 10.1056/NEJMoa1510093.

2.

Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.

Ciammella P, Filippi AR, Simontacchi G, Buglione M, Botto B, Mangoni M, Iotti C, Merli F, Marcheselli L, Bisi G, Ricardi U, Versari A.

Br J Radiol. 2016;89(1061):20150983. doi: 10.1259/bjr.20150983.

PMID:
27022777
3.

Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma.

Park JH, Yoon DH, Kim S, Park JS, Park CS, Sung H, Lee SW, Huh J, Suh C.

Ann Hematol. 2016 Apr;95(5):801-8. doi: 10.1007/s00277-016-2610-5.

PMID:
26883027
4.

Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.

Jalali A, Ha FJ, Chong G, Grigg A, Mckendrick J, Schwarer AP, Doig R, Hamid A, Hawkes EA.

Ann Hematol. 2016 Apr;95(5):809-16. doi: 10.1007/s00277-016-2611-4.

PMID:
26878861
5.

ABVD-Based Therapy for Hodgkin Lymphoma in Children and Adolescents: Lessons Learnt in a Tertiary Care Oncology Center in a Developing Country.

Jain S, Kapoor G, Bajpai R.

Pediatr Blood Cancer. 2016 Jun;63(6):1024-30. doi: 10.1002/pbc.25935.

PMID:
26855007
6.

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fosså A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW.

Blood. 2016 Mar 24;127(12):1531-8. doi: 10.1182/blood-2015-11-679407.

PMID:
26747247
7.

Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?

Specht L.

Curr Treat Options Oncol. 2016 Jan;17(1):4. doi: 10.1007/s11864-015-0377-x. Review.

PMID:
26739151
8.

Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.

Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G, Lombardo F, Lenzi A, Gandini L.

Hum Reprod. 2016 Feb;31(2):263-72. doi: 10.1093/humrep/dev310.

PMID:
26705149
9.

[IMMUNOHISTOCHEMICAL FACTORS OF SMALL-CELL LYMPHOMAS AND CHOICE OF TREATMENT WTTH LEVEL INCLUSION].

Kryachok IA, Aleksyk OM.

Lik Sprava. 2014 Dec;(12):40-4. Ukrainian.

PMID:
26638466
10.

Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.

Almagro-Casado E, Sánchez A, Cantos B, Salas C, Pérez-Callejo D, Provencio M.

Clin Transl Oncol. 2016 Jan;18(1):99-106. doi: 10.1007/s12094-015-1342-7.

PMID:
26530956
11.

Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond.

Ansell SM.

Am J Hematol. 2016 Jan;91(1):109-12. doi: 10.1002/ajh.24226. Review.

PMID:
26505486
12.

[A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma].

Tao Y, Kang S, Zhou L, Shi Y, Li Y, Sun Y.

Zhonghua Zhong Liu Za Zhi. 2015 Jun;37(6):466-71. Chinese.

PMID:
26463153
13.

Primary malignant non-hodgkin lymphoma of the talus.

Bansal S, Dharra N.

J Cancer Res Ther. 2015 Jul-Sep;11(3):649. doi: 10.4103/0973-1482.139602.

14.

Head and neck extra nodal NHL (HNENL)--Treatment Outcome and Pattern of failure--A Single Institution Experience.

Giridhar P, Mallick S, Bhasker S, Pathy S, Mohanti BK, Biswas A, Sharma A.

Asian Pac J Cancer Prev. 2015;16(15):6267-72.

15.

Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: Have We Got the Balance Right?

Illidge T.

Clin Oncol (R Coll Radiol). 2015 Aug;27(8):454-6. doi: 10.1016/j.clon.2015.05.007. No abstract available.

PMID:
26108883
16.
17.
18.

Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: A Haematologist's Perspective.

Follows GA.

Clin Oncol (R Coll Radiol). 2015 Aug;27(8):457-9. doi: 10.1016/j.clon.2015.05.008. No abstract available.

PMID:
26071896
19.

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1914-20. doi: 10.1016/j.bbmt.2015.06.003.

20.

Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.

Simontacchi G, Filippi AR, Ciammella P, Buglione M, Saieva C, Magrini SM, Livi L, Iotti C, Botto B, Vaggelli L, Re A, Merli F, Ricardi U.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1077-83. doi: 10.1016/j.ijrobp.2015.04.021.

PMID:
26031367
Items per page

Supplemental Content

Loading ...
Support Center